A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS.
- Registry ID
- PAC326 (PERSIST-2)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- CTI BIOPHARMA CORP
- Start date
- 2014-05-12
- Last update
- 2014-05-09
Conditions
- POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
- THROMBOCYTHEMIA MYELOFIBROSIS
- POST-POLYCYTHEMIA VERA MYELOFIBROSIS
- PRIMARY MYELOFIBROSIS (PMF)
- THROMBOCYTOPENIA
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE 3 CLINICAL
STUDY TO ASSESS EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B (P1101) IN ADULT
PATIENTS WITH PRE-FIBROTIC/EARLY PRIMARY MYELOFIBROSIS OR OVERT PRIMARY
MYELOFIBROSIS AT LOW OR INTERMEDIATE-1 RISK ACCORDING TO DIPSS PLUS (HOPEPMF): THE CORE STUDY AND ITS EXTENSION STUDY
- AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMOBOCYTOPENIA
- A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELETS COUNTS <50,000/MCL)
- A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE ACTIVITY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC, ANEMIC SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA (PV) MYELOFIBROSIS, OR POST ESSENTIAL THROMBOCYTHEMIA (ET) MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH JAK INHIBITOR THERAPY
- AN OPEN-LABEL, PHASE 2A/2B STUDY OF KRT-232 IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST¿POLYCYTHEMIA VERA MF (POST¿PV-MF), OR POST¿ESSENTIAL THROMBOCYTHEMIA MF (POST ET-MF) WHO HAVE FAILED RUXOLITINIB
View on source registry